Fairvalue-Calculator Fairvalue-Calculator
EN DE

MDLA (MDLA) Fair Value & Analysis

Healthcare · ID · Market cap 2.5T IDR

Price204.00 IDR
Fair Value517.75 IDR
Upside+153.8%
Quality94/100
Evidence: High Range 345.84 IDR – 699.84 IDR

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

MDLA (MDLA) currently trades at 204.00 IDR, while our model-based Fair Value estimate is 517.75 IDR — implying the stock looks roughly 153.8% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

PT Medela Potentia Tbk distributes and markets pharmaceutical and healthcare products, and medical devices in Indonesia and Cambodia. It also manufactures medical devices, including consumables and medical equipment for hospitals and laboratories. The company also processes medical device products; and digital platform and web portal activities for human use, as well as pharmaceutical products. In addition, the company develops GoApotik, a B2B2C platform for expanding its products to retailers, end consumers, and patients. PT Medela Potentia Tbk was founded in 2011 and is headquartered in Jakarta Selatan, Indonesia.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is MDLA (MDLA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 517.75 IDR versus a price of 204.00 IDR — about +154% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MDLA?
Our 21-model fair value for MDLA is 517.75 IDR (as of Jun 25, 2026), built from audited fundamentals. The current price is 204.00 IDR.
What is the quality score of MDLA?
MDLA has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.